IC
CGEM icon

Inscription Capital’s Cullinan Oncology CGEM Stock Holding History

Inscription Capital’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Hold
11,661
– – 0.02% 677
2026
Q1 		$166K Hold
11,661
– – 0.02% 638
2025
Q4 		$121K Buy
11,661
+377
+3% +$3.4K 0.01% 644
2025
Q3 		$66.9K Buy
+11,284
New +$82.6K 0.01% 629

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Inscription Capital's CGEM Position: Q2 2026 in Review

Inscription Capital held its Cullinan Oncology (CGEM) position steady in Q2 2026 at 11,661 shares worth $212K. The position accounts for 0.02% of the portfolio, ranked #677.

Inscription Capital first reported a position in CGEM in Q3 2025 and has held it in 4 quarters since. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Inscription Capital held 11,661 shares of Cullinan Oncology worth $212K as of Q2 2026.
  • Inscription Capital left its Cullinan Oncology share count unchanged in Q2 2026.
  • Cullinan Oncology made up 0.02% of Inscription Capital's portfolio in Q2 2026, its #677 holding.
  • Inscription Capital first reported a position in Cullinan Oncology in Q3 2025 and has held it in 4 quarters since.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.